UT MD Anderson· @UTMDAnderson · X·· 3 天前评分70
正文 · 机器翻译
明天在 ESMO 与 UT MD Anderson 一起参加位于 8 号馆 8006 号展位的“Meet the Experts”活动。
与我们的专家交流，探讨 KRAS 靶向疗法、乳腺癌治疗和下一代免疫疗法。
查看周五完整日程：http://spr.ly/6011BHXHcN #ESMO26 #EndCancer
@mvnegrao @champiatMD
1574 浏览 · 8 赞 · 3 转发 · 1 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org帖内回复
- KRAS Kickers@KRASKickers
@UTMDAnderson Dr. @mvnegrao - the New Era of KRAS-directed therapy
来源：UT MD Anderson · x.com